Toll样受体在冠心病中的研究进展及靶向药物分析

Research progress of Toll-like receptors in coronary heart disease and target drug analysis

张景 ¹王可 ¹来利红¹

扫码查看

作者信息

1. 河南科技大学临床医学院河南科技大学第一附属医院心内科,河南洛阳 471003
折叠

摘要

冠心病(CHD)是一种以慢性炎症刺激和斑块聚集为特征的心血管疾病(CVD),严重威胁着成千上万患者的生命安全.研究发现Toll样受体(TLRs)通过介导免疫激活参与多种炎性因子的产生,进而在CHD的发生发展中发挥着复杂的双向调节作用.靶向TLRs的治疗具有抗动脉粥样硬化的潜在作用.本文就TLRs信号在CHD中的作用机制及TLRs相关抗动脉粥样硬化药物的最新研究进展做一综述.

Abstract

Coronary heart disease(CHD)is a cardiovascular disease characterized by chronic inflammatory stimulation and plaque accumulation,which seriously threatens the lives of thousands of patients.It has been found that Toll-like receptors(TLRs)participate in the production of many inflammatory factors by mediating the immune activation,and play a complex bidirectional regulatory role in the occurrence and development of CHD.Treatment with targeted TLRs has a potential anti-atherosclerotic effect.This article reviewed the mechanism of TLRs signaling in CHD and the latest research progress in TLRs-related anti-atherosclerotic drugs.

关键词

冠状动脉粥样硬化性心脏病/Toll样受体/免疫/炎症/靶向药物

Key words

coronary heart disease/Toll-like receptor/immunity/inflammation/target drug

引用本文复制引用

基金项目

洛阳市科技发展计划项目(2001029A)

出版年

2024

中南药学

湖南省药学会

中南药学

CSTPCD

影响因子：0.736

ISSN：1672-2981

参考文献量2

段落导航